Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Roles of PCSK9 in the Pathogenesis of Periodontal Disease

In Press, (this is not the final "Version of Record"). Available online 27 September, 2023
Author(s): Motahareh Khosrojerdi, Željko Reiner, Negin Vatanparast, Tannaz Jamialahmadi, Prashant Kesharwani and Amirhossein Sahebkar*
Published on: 27 September, 2023

DOI: 10.2174/0929867331666230809100021

Price: $95

Abstract

Proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors are FDA-approved drugs recommended for high-risk patients with LDL-cholesterol (LDL-c) levels ≥ 70 mg/dl. Several studies have also investigated the relationship between PCSK9 and periodontitis. Specifically, studies have investigated the association between periodontitis and periodontal PCSK9 levels in humans, and periodontium status in PCSK9-knockout versus wild-type mice. While a positive association between periodontitis and periodontal PCSK9 levels has been noted, the findings on the comparison of periodontium status between PCSK9-knockout and wild-type mice have been inconsistent. Different methodologies among these studies may explain this discrepancy. Future experimental studies on the impact of pharmacological PCSK9 inhibition on periodontal status as well as observational studies comparing periodontium status between patients receiving PCSK9 inhibitors and those receiving other lipid-lowering drugs will shed light on the role of PCSK9 in periodontal health and disease.

[1]
Rosenson, R.S.; Hegele, R.A.; Fazio, S.; Cannon, C.P. The evolving future of PCSK9 inhibitors. J. Am. Coll. Cardiol., 2018, 72(3), 314-329.
[http://dx.doi.org/10.1016/j.jacc.2018.04.054] [PMID: 30012326]
[2]
Jia, X.; Al Rifai, M.; Saeed, A.; Ballantyne, C.M.; Virani, S.S. PCSK9 inhibitors in the management of cardiovascular risk: A practical guidance. Vasc. Health Risk Manag., 2022, 18, 555-566.
[http://dx.doi.org/10.2147/VHRM.S275739] [PMID: 35898405]
[3]
Sahebkar, A.; Watts, G.F. New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin. Ther., 2013, 35(8), 1082-1098.
[http://dx.doi.org/10.1016/j.clinthera.2013.06.019] [PMID: 23932550]
[4]
Zijlstra, L.E.; Mooijaart, S.P.; Jukema, J.W. PCSK9 inhibition in high-risk patients. Aging., 2019, 11(23), 10791-10792.
[http://dx.doi.org/10.18632/aging.102621] [PMID: 31829977]
[5]
Cesaro, A.; Bianconi, V.; Gragnano, F.; Moscarella, E.; Fimiani, F.; Monda, E.; Scudiero, O.; Limongelli, G.; Pirro, M.; Calabrò, P. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. Biofactors., 2020, 46(3), 367-380.
[http://dx.doi.org/10.1002/biof.1619] [PMID: 31999032]
[6]
Macchi, C.; Ferri, N.; Sirtori, C.R.; Corsini, A.; Banach, M.; Ruscica, M. Proprotein convertase subtilisin/kexin type 9. Am. J. Pathol., 2021, 191(8), 1385-1397.
[http://dx.doi.org/10.1016/j.ajpath.2021.04.016] [PMID: 34019847]
[7]
Jamialahmadi, T.; Panahi, Y.; Safarpour, M.A.; Ganjali, S.; Chahabi, M.; Reiner, Z.; Solgi, S.; Vahedian-azimi, A.; Kianpour, P.; Banach, M.; Sahebkar, A. Association of serum PCSK9 levels with antibiotic resistance and severity of disease in patients with bacterial infections admitted to intensive care units. J. Clin. Med., 2019, 8(10), 1742.
[http://dx.doi.org/10.3390/jcm8101742] [PMID: 31635200]
[8]
Mahboobnia, K.; Pirro, M.; Marini, E.; Grignani, F.; Bezsonov, E.E.; Jamialahmadi, T.; Sahebkar, A. PCSK9 and cancer: Rethinking the link. Biomed. Pharmacother., 2021, 140, 111758.
[http://dx.doi.org/10.1016/j.biopha.2021.111758] [PMID: 34058443]
[9]
Momtazi-Borojeni, A.A.; Sabouri-Rad, S.; Gotto, A.M., Jr; Pirro, M.; Banach, M.; Awan, Z.; Barreto, G.E.; Sahebkar, A. PCSK9 and inflammation: A review of experimental and clinical evidence. Eur. Heart J. Cardiovasc. Pharmacother., 2019, 5(4), 237-245.
[http://dx.doi.org/10.1093/ehjcvp/pvz022] [PMID: 31236571]
[10]
Kassebaum, N.J.; Bernabé, E.; Dahiya, M.; Bhandari, B.; Murray, C.J.L.; Marcenes, W. Global burden of severe periodontitis in 1990-2010: A systematic review and meta-regression. J. Dent. Res., 2014, 93(11), 1045-1053.
[http://dx.doi.org/10.1177/0022034514552491] [PMID: 25261053]
[11]
Thermos, G.; Tosios, K.I. Gingival ischemia and petechiae in a patient medicated with PCSK9 inhibitor for hypercholesterolemia: An adverse drug event? Clinic. Adv. Periodontics., 2019, 9(1), 20-23.
[http://dx.doi.org/10.1002/cap.10043] [PMID: 31490035]
[12]
Tabeta, K.; Hosojima, M.; Nakajima, M.; Miyauchi, S.; Miyazawa, H.; Takahashi, N.; Matsuda, Y.; Sugita, N.; Komatsu, Y.; Sato, K.; Ishikawa, T.; Akiishi, K.; Yamazaki, K.; Kato, K.; Saito, A.; Yoshie, H. Increased serum PCSK9, a potential biomarker to screen for periodontitis, and decreased total bilirubin associated with probing depth in a Japanese community survey. J. Periodontal Res., 2018, 53(3), 446-456.
[http://dx.doi.org/10.1111/jre.12533] [PMID: 29516504]
[13]
Rughwani, R.R.; Cholan, P.K.; Victor, D.J.; Ilango, P.; Cherian, S.M.; Rughwani, R.N.; Tadepalli, A. Evaluation of serum and salivary PCSK9 and IL6 and its association with periodontal inflammation and atherosclerotic cardiovascular diseases. J. Oral Biol. Craniofac. Res., 2022, 12(5), 633-638.
[http://dx.doi.org/10.1016/j.jobcr.2022.08.013] [PMID: 36042970]
[14]
Yokoji-Takeuchi, M.; Tabeta, K.; Takahashi, N.; Arimatsu, K.; Miyazawa, H.; Matsuda-Matsukawa, Y.; Sato, K.; Yamada, M.; Yamazaki, K. Indirect regulation of PCSK9 gene in inflammatory response by Porphyromonas gingivalis infection. Heliyon., 2019, 5(1), e01111.
[http://dx.doi.org/10.1016/j.heliyon.2018.e01111] [PMID: 30671557]
[15]
Miyazawa, H.; Honda, T.; Miyauchi, S.; Domon, H.; Okui, T.; Nakajima, T. Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration. Clin Chim Acta., 2012, 413(1-2), 154-159.
[http://dx.doi.org/10.1016/j.cca.2011.09.023]
[16]
Miyazawa, H.; Tabeta, K.; Miyauchi, S.; Aoki-Nonaka, Y.; Domon, H.; Honda, T.; Nakajima, T.; Yamazaki, K. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice. Lipids Health Dis., 2012, 11(1), 121.
[http://dx.doi.org/10.1186/1476-511X-11-121] [PMID: 22992388]
[17]
Sun, H.L.; Wu, Y.R.; Song, F.F.; Gan, J.; Huang, L.Y.; Zhang, L.; Huang, C. Role of PCSK9 in the development of mouse periodontitis before and after treatment: A double-edged sword. J. Infect. Dis., 2018, 217(4), 667-680.
[http://dx.doi.org/10.1093/infdis/jix574] [PMID: 29294034]
[18]
Huang, L.; Wu, H.; Wu, Y.; Song, F.; Zhang, L.; Li, Z.; Sun, H.; Huang, C. Pcsk9 knockout aggravated experimental apical periodontitis via LDLR. J. Dent. Res., 2022, 101(1), 83-92.
[http://dx.doi.org/10.1177/00220345211015128] [PMID: 34036816]
[19]
Baumeister, S.E.; Holtfreter, B.; Reckelkamm, S.L.; Kocher, T.; Alayash, Z.; Ehmke, B. Genotype-driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis. J. Clin. Periodontol., 2022, 50(1), 114-120.
[PMID: 36054135]
[20]
Yuan, Y.; Wu, W.; Sun, S.; Zhang, Y.; Chen, Z. PCSK9: A potential therapeutic target for sepsis. J. Immunol. Res., 2020, 2020, 1-8.
[http://dx.doi.org/10.1155/2020/2687692] [PMID: 33123601]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy